1. Home
  2. For Industry
  3. FDA User Fee Programs
  4. Prescription Drug User Fee Amendments
  5. Upcoming EL-PFDD Meetings
  1. Prescription Drug User Fee Amendments

Upcoming EL-PFDD Meetings

To promote transparency and communication, FDA is sharing a list of disease areas where a letter of intent (LOI) has been submitted and ongoing plans exist for a future Externally-Led PFDD meeting. While multiple organizations may be working together, the organizations listed below are the primary points of contact for any questions regarding their EL-PFDD meeting.

FDA does not conduct Externally-Led PFDD meetings and a listing on this webpage does not reflect endorsement.

Disease or ConditionOrganization Submitting LOIOrganization ContactAnticipated Meeting Date
Infertility and Advancing Therapeutic Solutions for In Vitro Fertilization (IVF)Alliance for Fertility Preservation

Joyce Reinecke

jreinecke@a4fp.org

March 26, 2026
Central Nervous System Disseminated Coccidiomycosis (Meningitis)MYCARE Foundation

Rob Purdie

rpurdie@fightfungus.org

April 14, 2026
Genetic CardiomyopathiesHypertrophic Cardiomyopathy Association

Hypertrophic Cardiomyopathy Association

support@4hcm.org

April 23, 2026
Diamond-Blackfan Anemia Syndrome (DBAS)The Styrke Foundation for Rare Disease and Treatment

Anne Yang

ayang@styrke.org

May 1, 2026
Down Syndrome-Associated Alzheimer’s Disease (DS-AD)National Down Syndrome Society

National Down Syndrome Society

pfdd@ndss.org

June 2, 2026
Maternal Alloimmunization and Hemolytic Disease of the Fetus and Newborn (HDFN)Maternal Alloimmunization Foundation

Stephanie McCary

stephaniemccary@alloimmunization.org

July 20, 2026
Spinal Cord Injury (SCI)Spinal Cord Injury Perspectives Initiative

Gabriela Ocampo

gocampo@nasciconsortium.org

September 29, 2026
Fanconi Anemia (FA)Fanconi Cancer Foundation

Andrea Ronan

communitysupport@fanconi.org

October 3, 2026
SCN2AFamilieSCN2A Foundation

SCN2A Foundation

advocacy@scn2a.org

October 23, 2026
Giant Axonal Neuropathy (GAN)Hannah's Hope Fundhhf4gan@gmail.comNovember 8, 2026
MucormycosisMYCARE Foundation

Rob Purdie

rpurdie@fightfungus.org

November 10, 2026

Questions?

To contact FDA’s CDER Patient-Focused Drug Development Program Staff, please email patientfocused@fda.hhs.gov.

To get updates about CDER’s Patient-Focused Drug Development programs, subscribe to our free email subscription service at the bottom of the page.

Back to CDER Patient-Focused Drug Development Homepage.

Patient-Focused Drug Development

Get regular FDA email updates delivered on this topic to your inbox.
Back to Top